PCRX Annual Current Liabilities
$97.38 M
-$50.39 M-34.10%
31 December 2023
Summary:
As of January 20, 2025, PCRX annual total current liabilities is $97.38 million, with the most recent change of -$50.39 million (-34.10%) on December 31, 2023. During the last 3 years, it has fallen by -$155.94 million (-61.56%). PCRX annual current liabilities is now -81.31% below its all-time high of $521.12 million, reached on December 31, 2021.PCRX Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PCRX Quarterly Current Liabilities
$306.40 M
+$213.71 M+230.57%
30 September 2024
Summary:
As of January 20, 2025, PCRX quarterly total current liabilities is $306.40 million, with the most recent change of +$213.71 million (+230.57%) on September 30, 2024. Over the past year, it has increased by +$212.74 million (+227.14%). PCRX quarterly current liabilities is now -41.20% below its all-time high of $521.12 million, reached on December 31, 2021.PCRX Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PCRX Current Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -34.1% | +227.1% |
| 3 y3 years | -61.6% | +0.4% |
| 5 y5 years | +60.5% | +0.4% |
PCRX Current Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -81.3% | at low | -41.2% | +230.6% |
| 5 y | 5-year | -81.3% | at low | -41.2% | +334.1% |
| alltime | all time | -81.3% | +587.9% | -41.2% | +2313.0% |
Pacira BioSciences Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $306.40 M(+230.6%) |
| June 2024 | - | $92.69 M(-0.8%) |
| Mar 2024 | - | $93.44 M(-4.0%) |
| Dec 2023 | $97.38 M(-34.1%) | $97.38 M(+4.0%) |
| Sept 2023 | - | $93.66 M(-14.0%) |
| June 2023 | - | $108.91 M(+10.3%) |
| Mar 2023 | - | $98.70 M(-33.2%) |
| Dec 2022 | $147.77 M(-71.6%) | $147.77 M(+12.4%) |
| Sept 2022 | - | $131.53 M(-1.2%) |
| June 2022 | - | $133.18 M(-56.3%) |
| Mar 2022 | - | $305.07 M(-41.5%) |
| Dec 2021 | $521.12 M(+105.7%) | $521.12 M(+130.8%) |
| Sept 2021 | - | $225.79 M(-1.3%) |
| June 2021 | - | $228.69 M(-1.5%) |
| Mar 2021 | - | $232.08 M(-8.4%) |
| Dec 2020 | $253.33 M(+135.3%) | $253.33 M(+193.6%) |
| Sept 2020 | - | $86.27 M(+22.2%) |
| June 2020 | - | $70.58 M(-12.1%) |
| Mar 2020 | - | $80.31 M(-25.4%) |
| Dec 2019 | $107.67 M(+77.5%) | $107.67 M(+12.3%) |
| Sept 2019 | - | $95.84 M(+15.5%) |
| June 2019 | - | $83.00 M(+40.7%) |
| Mar 2019 | - | $58.99 M(-2.8%) |
| Dec 2018 | $60.66 M(+7.9%) | $60.66 M(+11.3%) |
| Sept 2018 | - | $54.52 M(+2.8%) |
| June 2018 | - | $53.02 M(+9.6%) |
| Mar 2018 | - | $48.37 M(-14.0%) |
| Dec 2017 | $56.22 M | $56.22 M(+7.4%) |
| Sept 2017 | - | $52.34 M(-9.0%) |
| June 2017 | - | $57.51 M(+26.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2017 | - | $45.65 M(+1.8%) |
| Dec 2016 | $44.84 M(-70.1%) | $44.84 M(-69.5%) |
| Sept 2016 | - | $146.83 M(-2.4%) |
| June 2016 | - | $150.44 M(+2.9%) |
| Mar 2016 | - | $146.14 M(-2.4%) |
| Dec 2015 | $149.79 M(+7.0%) | $149.79 M(+3.0%) |
| Sept 2015 | - | $145.41 M(-0.0%) |
| June 2015 | - | $145.47 M(+6.6%) |
| Mar 2015 | - | $136.45 M(-2.5%) |
| Dec 2014 | $140.01 M(+14.8%) | $140.01 M(+3.5%) |
| Sept 2014 | - | $135.22 M(+4.4%) |
| June 2014 | - | $129.51 M(+6.5%) |
| Mar 2014 | - | $121.59 M(-0.3%) |
| Dec 2013 | $121.94 M(+761.4%) | $121.94 M(+4.2%) |
| Sept 2013 | - | $116.97 M(+638.7%) |
| June 2013 | - | $15.84 M(+24.7%) |
| Mar 2013 | - | $12.70 M(-10.3%) |
| Dec 2012 | $14.16 M(-55.6%) | $14.16 M(-28.6%) |
| Sept 2012 | - | $19.83 M(+30.1%) |
| June 2012 | - | $15.24 M(-20.5%) |
| Mar 2012 | - | $19.16 M(-40.0%) |
| Dec 2011 | $31.91 M(+95.5%) | $31.91 M(+79.0%) |
| Sept 2011 | - | $17.83 M(+2.0%) |
| June 2011 | - | $17.48 M(-11.1%) |
| Mar 2011 | - | $19.66 M(+20.5%) |
| Dec 2010 | $16.32 M(+13.2%) | $16.32 M(+18.2%) |
| Sept 2010 | - | $13.81 M(-2.4%) |
| June 2010 | - | $14.14 M(-1.9%) |
| Dec 2009 | $14.42 M(-15.3%) | $14.42 M |
| Dec 2008 | $17.02 M | - |
FAQ
- What is Pacira BioSciences annual total current liabilities?
- What is the all time high annual current liabilities for Pacira BioSciences?
- What is Pacira BioSciences annual current liabilities year-on-year change?
- What is Pacira BioSciences quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Pacira BioSciences?
- What is Pacira BioSciences quarterly current liabilities year-on-year change?
What is Pacira BioSciences annual total current liabilities?
The current annual current liabilities of PCRX is $97.38 M
What is the all time high annual current liabilities for Pacira BioSciences?
Pacira BioSciences all-time high annual total current liabilities is $521.12 M
What is Pacira BioSciences annual current liabilities year-on-year change?
Over the past year, PCRX annual total current liabilities has changed by -$50.39 M (-34.10%)
What is Pacira BioSciences quarterly total current liabilities?
The current quarterly current liabilities of PCRX is $306.40 M
What is the all time high quarterly current liabilities for Pacira BioSciences?
Pacira BioSciences all-time high quarterly total current liabilities is $521.12 M
What is Pacira BioSciences quarterly current liabilities year-on-year change?
Over the past year, PCRX quarterly total current liabilities has changed by +$212.74 M (+227.14%)